The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...
Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...
By Jonathan Stempel June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...
Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S. District Court for the District of Delaware. Vyndamax remains the market leader ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results